Chronic hepatitis C

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Insulin resistance was a better predictor of sustained virological response than steatosis or cirrhosis in multivariable models, and is the only non-invasive measure among the three correlated predict

Effect: improvement; IR model had smaller -2 log likelihood value than steatosis or cirrhosis models

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)

Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the fi

Effect: adverse; 24% treatment discontinuation (23/96)